Abstract
The purpose of this work is a construction of the basic manner of a human brain-tumor therapy by using an immunovesicle (antibody-immobilized vesicle) in DDS. The ERM5-1 cell was applied as a model cell of human brain-tumor, which was a mouse cell made by transgenic technology. The human brain-tumor cell was found to have a specific antigen of EGFR (Epidermal Growth Factor Receptor). The ERM5-1 cell has the antigen EGFR and the cell can be applied as a model cell of human brain-tumor cell. Anti-EGFR antibody was immobilized on the surface of the vesicle as follows. The human anti-EGFR antibody (IgG) was preliminary immobilized to a protein A, which has a binding site to Fc fragment of IgG. The EGFR-protein A complex was immobilized to a vesicle by means of the two-step emulsification. Thus, the human anti-EGFR antibody was successfully immobilized orientated to the outer direction of the vesicle surface. It was fluorometrically confirmed that the specific antigen-antibody affinity between the antibody of the vesicle and EGFR on the ERM5-1 cell well functioned in vitro experiments. In the vesicle, Taxsotere of anti-tumor drug was entrapped for increasing the anti-tumor effect of the vesicle. It was also confirmed from in vitro experiments that anti-tumor effect of the immunovesicle to the ERM5-1 cell was superior to a normal vesicle (non-immunovesicle). Moreover, the in vivo experiments of anti-tumor effect to the ERM5-1 cell were carried out administrating the Taxotere-entrapped immunovesicle into nude mice to which ERM5-1 cell was implanted. Superior anti-tumor effect to the ERM5-1 cell in the mice could be observed to that of the normal vesicle.
